At‐home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash
Pediatric Pulmonology2022Vol. 57(7), pp. 1779–1781
Citations Over TimeTop 14% of 2022 papers
Abstract
Abstract As elexacaftor/tezacaftor/ivacaftor has proven to have robust clinical efficacy for eligible persons with cystic fibrosis, desensitization should be offered to those with maculopapular eruption hypersensitivity reactions to achieve tolerance. As presented in this case, if provided with tools for crushing and mixing the medication, a successful escalation protocol can be completed at home without coordinating the help of a compound pharmacy.
Related Papers
- → Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients(2022)20 cited
- → Severe urticarial rash as the initial symptom of COVID-19 infection(2021)16 cited
- → Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance(2023)4 cited
- → ‘Triple therapy’ (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis(2020)12 cited
- Sparing of leprosy macule in ampicillin hypersensitivity rash.(1988)